A prospective, randomized, blinded, placebo-controlled multisite clinical study of bedinvetmab, a canine monoclonal antibody targeting nerve growth factor, in dogs with osteoarthritis
- PMID: 34565678
- DOI: 10.1016/j.vaa.2021.08.001
A prospective, randomized, blinded, placebo-controlled multisite clinical study of bedinvetmab, a canine monoclonal antibody targeting nerve growth factor, in dogs with osteoarthritis
Abstract
Objective: Bedinvetmab is a canine monoclonal antibody targeting nerve growth factor. This study evaluated the efficacy and safety of bedinvetmab for alleviation of pain associated with osteoarthritis in dogs.
Study design: Double-blind, randomized, multicentre, placebo-controlled study.
Animals: Client-owned dogs (n = 287) with osteoarthritis.
Methods: Dogs were randomized (1:1) to subcutaneous injection with placebo (saline, n = 146) or bedinvetmab (0.5-1.0 mg kg-1, n = 141) administered monthly. After 3 months, 89 bedinvetmab-treated dogs that responded positively based on owner and veterinarian assessments were administered up to six additional doses of bedinvetmab in a single-armed open-label continuation phase. The primary efficacy end point was treatment success based on the owner-assessed canine brief pain inventory (CBPI) on day 28. Treatment success was defined as ≥ 1 reduction in pain severity score (0-10) and ≥ 2 in pain interference score (0-10).
Results: Percentage treatment success was significantly greater in the bedinvetmab group than in the placebo group from day 7 through all assessed time points (p ≤ 0.0025). On day 28, 43.5% of dogs achieved treatment success with bedinvetmab compared with placebo (16.9%) (p = 0.0017). Treatment success continued through days 56 (50.8%) and 84 (48.2%) in the bedinvetmab group and was < 25% in the placebo group at all time points. Sustained efficacy was demonstrated in the continuation phase. Adverse health events occurred at similar frequencies in both groups. They were considered typical for a population of dogs with osteoarthritis and not related to study treatment. Treatment with bedinvetmab demonstrated a significant effect on all three components of CBPI-pain interference, pain severity, quality of life.
Conclusions and clinical relevance: This study demonstrated the effectiveness and safety of bedinvetmab administered monthly for up to 9 months at 0.5-1.0 mg kg-1 for alleviation of pain associated with canine osteoarthritis.
Keywords: analgesia; canine osteoarthritis; degenerative joint disease; monoclonal antibody; pain; pain management.
Copyright © 2021 Zoetis Inc. Published by Elsevier Ltd.. All rights reserved.
Similar articles
-
A prospective, randomized, double-blind, placebo-controlled multisite, parallel-group field study in dogs with osteoarthritis conducted in the United States of America evaluating bedinvetmab, a canine anti-nerve growth factor monoclonal antibody.Vet Anaesth Analg. 2023 Sep;50(5):446-458. doi: 10.1016/j.vaa.2023.06.003. Epub 2023 Jun 19. Vet Anaesth Analg. 2023. PMID: 37541934
-
A Prospective, Randomized, Masked, Placebo-Controlled Multisite Clinical Study of Grapiprant, an EP4 Prostaglandin Receptor Antagonist (PRA), in Dogs with Osteoarthritis.J Vet Intern Med. 2016 May;30(3):756-63. doi: 10.1111/jvim.13948. Epub 2016 Apr 13. J Vet Intern Med. 2016. PMID: 27075237 Free PMC article. Clinical Trial.
-
Enflicoxib for canine osteoarthritis: A randomized, blind, multicentre, non-inferiority clinical trial compared to mavacoxib.PLoS One. 2022 Sep 20;17(9):e0274800. doi: 10.1371/journal.pone.0274800. eCollection 2022. PLoS One. 2022. PMID: 36126039 Free PMC article.
-
Advances in the pharmaceutical treatment options for canine osteoarthritis.J Small Anim Pract. 2022 Oct;63(10):721-738. doi: 10.1111/jsap.13495. Epub 2022 Mar 14. J Small Anim Pract. 2022. PMID: 35285032 Free PMC article. Review.
-
A 2022 Systematic Review and Meta-Analysis of Enriched Therapeutic Diets and Nutraceuticals in Canine and Feline Osteoarthritis.Int J Mol Sci. 2022 Sep 8;23(18):10384. doi: 10.3390/ijms231810384. Int J Mol Sci. 2022. PMID: 36142319 Free PMC article. Review.
Cited by
-
Development and validation of a quality of life and treatment satisfaction measure in canine osteoarthritis.Front Vet Sci. 2024 May 3;11:1377019. doi: 10.3389/fvets.2024.1377019. eCollection 2024. Front Vet Sci. 2024. PMID: 38764853 Free PMC article.
-
Pulsed shortwave electromagnetic field therapy increases quality of life in canines with symptoms of osteoarthritics.Vet Med Sci. 2024 May;10(3):e1408. doi: 10.1002/vms3.1408. Vet Med Sci. 2024. PMID: 38516818 Free PMC article.
-
COAST Development Group's international consensus guidelines for the treatment of canine osteoarthritis.Front Vet Sci. 2023 Aug 3;10:1137888. doi: 10.3389/fvets.2023.1137888. eCollection 2023. Front Vet Sci. 2023. PMID: 37601753 Free PMC article. Review.
-
Progress in palliation: Managing pain caused by cancer in veterinary medicine.Can Vet J. 2023 Aug;64(8):789-791. Can Vet J. 2023. PMID: 37529397 Free PMC article. No abstract available.
-
Serum nerve growth factor in horses with osteoarthritis-associated lameness.J Vet Intern Med. 2023 May-Jun;37(3):1201-1208. doi: 10.1111/jvim.16718. Epub 2023 Apr 21. J Vet Intern Med. 2023. PMID: 37083137 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical